Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

European Innovation Council · Running

Cellularity The critical shift to single-cell formats in functional analyses of living cells

Coordinator
Samplix Aps, Denmark
Runs
1 August 2023 to 31 July 2025
Status
Running
EU funding
€2.5m
Total cost
€4.9m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190144395

What the project is doing

In the project's own words, from its summary on CORDIS.

The incredible potential of cell and immune therapy (CIT) is limited by technical challenges related to the standard analysis of immune cells in bulk, which neglects their heterogeneity. Single-cell functional resolution is essential to understand the full potential of immune cells. Current single-cell technologies are limited, low-throughput, high-cost and lack robustness, prohibitive for their implementation in CIT R&D, manufacturing and patient stratification.

Samplix is developing Xplore, an all-in-one multiparameter single-cell analyser and sorter for screening, selection and expansion of immune cells based on functionality and potency. Xplore is a cost-effective solution that delivers higher throughput and sensitivity than current solutions, being compatible with CIT research workflows. Unlocking the full potential of CIT supports the faster and efficient development of new personalized therapies to treat serious diseases such as cancer, autoimmune diseases, and viral infections.

Topics

Who is involved

OrganisationCityCountryRole
Samplix ApsBirkerodDenmarkCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI